Candel reports sustained immune biomarkers >2 years post-aglatimagene in prostate cancer phase 3
Candel Therapeutics presented biomarker data from a completed phase 3 trial of aglatimagene besadenovec showing sustained immune remodeling beyond two years in localized intermediate- to high-risk prostate cancer patients at ASTRO 2026.
How Oyticker scores a story: impact and confidence describe the information, not a probability that a price moves.
What happened
Candel (CADL) disclosed new biomarker findings from its phase 3 clinical trial of aglatimagene besadenovec in localized intermediate- to high-risk prostate cancer, presented at the American Society for Radiation Oncology Annual Meeting 2026 on September 30, 2026. The data demonstrate sustained immune remodeling persisting more than two years after treatment.
Why it matters
Durability of immune response beyond two years in a completed phase 3 trial may support clinical efficacy and differentiation in the prostate cancer immunotherapy space. Sustained biomarker changes could strengthen regulatory positioning and inform label claims if clinical endpoints align with immune durability.
Market transmission
Positive phase 3 biomarker durability → potential strengthening of clinical narrative for regulatory submission → improved probability of approval and market positioning → valuation support for clinical-stage asset. Sustained immune response may reduce recurrence risk, extending patient survival benefit and commercial addressable population.
What to watch
Phase 3 primary efficacy endpoint results (recurrence-free survival, overall survival); regulatory feedback on biomarker data sufficiency for approval; competitive positioning versus established prostate cancer immunotherapies; timeline to regulatory submission and decision.
Source:GlobeNewswire US
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.